Skip to main content
SpringerLink
Log in

Tandospirone

  • New Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

▴ Tandospirone is a new addition to the azapirone class of anxiolytics, which may be useful for the long term treatment of anxiety and depressive neuroses.

▴ It is a serotonin (5-hydroxytryptamine; 5-HT)lA receptor agonist that has anxiolytic effects.

▴ Unlike benzodiazepines, the anxiolytic and anti-depressant effects of tandospirone can be separated from the sedative, anticonvulsant and muscle relaxant effects.

▴ The abuse potential of tandospirone appears to be lower than that of benzodiazepines.

▴ Tandospirone has anxiolytic effects similar to those of diazepam in patients with various different neuroses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hamik A, Oksenberg D, Fischette C, et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990 Jul 15; 28: 99–109

    Article  PubMed  CAS  Google Scholar 

  2. Wieland S, Fischette CT, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology 1993 Jun; 32: 561–73

    Article  PubMed  CAS  Google Scholar 

  3. Tanaka H, Shimizu H, Kumasaka Y, et al. Autoradiographic localization and pharmacological characterization of [3H]tando-spirone binding sites in the rat brain. Brain Res 1991; 546(2): 181–9

    Article  PubMed  CAS  Google Scholar 

  4. Shimizu H, Kumasaka Y, Tanaka H. Anticonflict action of tandospirone in a modified Geller-Scifter conflict test in rats. Jpn J Pharmacol 1992 Mar; 58: 283–9

    Article  PubMed  CAS  Google Scholar 

  5. Shimizu H, Tatsuno T, Tanaka H, et al. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 1992 May; 59: 105–12

    Article  PubMed  CAS  Google Scholar 

  6. Pollard GT, Nanry KP, Howard JL. Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol 1992 Oct 20; 221: 297–305

    Article  PubMed  CAS  Google Scholar 

  7. Wieland S, Lucki I. Antidepressant-like activity of 5-HTlA agonists measured with the forced swim test. Psychopharmacol-ogy (Berl) 1990; 101: 497–504

    Article  CAS  Google Scholar 

  8. Sannerud CA, Ator NA, Griffiths RR. Behavioral pharmacology of tandospirone in baboons — chronic administration and withdrawal, self-injection and drug discrimination. Drug Alcohol Depend 1993 May; 32: 195–208

    Article  PubMed  CAS  Google Scholar 

  9. Shimizu H, Hirose A, Tatsuno T, et al. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J Pharmacol 1987 Dec; 45: 493–500

    Article  PubMed  CAS  Google Scholar 

  10. Okada F, Torii Y, Saito H, et al. Antiemetic effects of serotonergic 5-HTlA-receptor agonists in Suncus murinus. Jpn J Pharmacol 1994 Feb;64: 109–14

    Article  PubMed  CAS  Google Scholar 

  11. Nakamura M, Sugimoto S, Kurita H, et al. General pharmacology of tandospirone. Clin Rep 1992 May; 26(5): 27–50

    Google Scholar 

  12. Tsuji R, Ohno Y, Hirose A, et al. Effects of tandospirone, a 5-HTlA receptor-related anxiolytic, on the pressor response elicited by stimulation of the posterior hypothalamus in cats. Arch Int Pharmacodyn Ther 1991 May-Jun; 311: 131–43

    PubMed  CAS  Google Scholar 

  13. Evans SM, Troisi Jr II, Griffiths RR. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 1994 Nov; 271: 683–94

    PubMed  CAS  Google Scholar 

  14. Murasaki M, Mori A, Endo S, et al. Efficacy of a new anxiolytic, tandospirone (SM-3997) on neurosis. A comparative double-blind study with diazepam [in Japanese]. Rinsho Hyoka 1992; 20(2): 295–329

    Google Scholar 

  15. Greenblatt DJ, Harmatz JS, Zinny MA. Pharmacokinetics and dynamics of ascending single doses of tandospirone in healthy volunteers [abstract]. J Clin Pharmacol 1992 Aug; 32: 751

    Google Scholar 

  16. Suzuki M, Uchiumi M, Murasaki M. Effects of tandospirone, a 5-HTlA receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Yakubutsu Scishin Kodo 1993 Aug; 13: 213–24

    CAS  Google Scholar 

  17. Kikuchi N, Goto U, Suzuki J, et al. Double blind study of tandospirone (SM-3997) on essential hypertension as meaning of cardiovascular psychosomatic disease: comparative study with diazepam [in Japanese]. Clin Rep 1992 Sep; 26(10): 4351–67

    Google Scholar 

  18. Oseekey KB, Wood SG, Chasseaud LF, et al. Pharmacokinetics and metabolism of tandospirone in man [abstract]. Pharm Res 1992 Oct; 9 Suppl.: 300

    Google Scholar 

  19. Murasaki M, Mori A, Endo S, et al. Late phase II study of a new anxiolytic, SM-3997 (tandospirone) on neurosis [in Japanese]. Rinsho Hyoka 1992; 20(2): 259–93

    Google Scholar 

  20. Murasaki M, Mori A, Hasegawa K, et al. A clinical evaluation of anti-anxiety drug, SM-3997 (tandospirone), on various neurosis — early phase II study at Tokyo area [in Japanese]. Kiso to Rinsho 1992 Sept; 26(10): 65–78

    Google Scholar 

  21. Tsutsui S, Saito T, Katsura T. Double blind comparative study of tandospirone (SM-3997) on neurosis — placebo controlled dose-finding study. Kiso to Rinsho 1992 Sept; 26(10): 127–50

    Google Scholar 

  22. Tamai H, Komaki G, Kubota S, et al. The clinical efficacy of a 5-HTlA agonist, SM-3997, in the treatment of bulimia. Int J Obes 1990 Mar; 14: 289–92

    PubMed  CAS  Google Scholar 

  23. Kimura M, Sakata T, Nakagawa T, et al. Clinical evaluation of tandospirone (SM-3997), on psychosomatic diseases with gastrointestinal complaints. A comparative double-blind controlled study with diazepam and placebo [in Japanese]. Rinsho Hyoka 1992; 20(2): 225–57

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Lee B. Barradell & Andrew Fitton

Authors
  1. Lee B. Barradell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Fitton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barradell, L.B., Fitton, A. Tandospirone. CNS Drugs 5, 147–153 (1996). https://doi.org/10.2165/00023210-199605020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199605020-00006

Keywords

Search

Navigation